The tumor-enriched small molecule gambogic amide suppresses glioma by targeting WDR1-dependent cytoskeleton remodeling.

Abstract

Glioma is the most prevalent brain tumor, presenting with limited treatment options, while patients with malignant glioma and glioblastoma (GBM) have poor prognoses. The physical obstacle to drug delivery imposed by the blood‒brain barrier (BBB) and glioma stem cells (GSCs), which are widely recognized as crucial elements contributing to the unsatisfactory clinical outcomes. In this study, we found a small molecule, gambogic amide (GA-amide), exhibited the ability to effectively penetrate the blood-brain barrier (BBB) and displayed a notable enrichment within the tumor region. Moreover, GA-amide exhibited significant efficacy in inhibiting tumor growth across various in vivo glioma models, encompassing transgenic and primary patient-derived xenograft (PDX) models. We further performed a genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) knockout screen to determine the druggable target of GA-amide. By the combination of the cellular thermal shift assay (CETSA), the drug affinity responsive target stability (DARTS) approach, molecular docking simulation and surface plasmon resonance (SPR) analysis, WD repeat domain 1 (WDR1) was identified as the direct binding target of GA-amide. Through direct interaction with WDR1, GA-amide promoted the formation of a complex involving WDR1, MYH9 and Cofilin, which accelerate the depolymerization of F-actin to inhibit the invasion of patient-derived glioma cells (PDCs) and induce PDC apoptosis via the mitochondrial apoptotic pathway. In conclusion, our study not only identified GA-amide as an effective and safe agent for treating glioma but also shed light on the underlying mechanisms of GA-amide from the perspective of cytoskeletal homeostasis.

• Authors: Jiaorong Qu, Bojun Qiu, Yuxin Zhang, Yan Hu, Zhixing Wang, Zhiang Guan, Yiming Qin, Tongtong Sui, Fan Wu, Boyang Li, Wei Han, Xiaozhong Peng
• Journal: Signal transduction and targeted therapy (Signal Transduct Target Ther) Vol. 8 Issue 1 Pg. 424 (Nov 08 2023) ISSN: 2059-3635 [Electronic] England
• PMID: 37935665 (Publication Type: Journal Article)
• Copyright: © 2023. The Author(s).

Chemical References

• gambogic amide
• Amides
• WDR1 protein, human
• Microfilament Proteins

Topics

• Humans
• Molecular Docking Simulation
• Cell Line, Tumor
• Glioma (drug therapy, genetics, metabolism)
• Cytoskeleton
• Amides
• Microfilament Proteins (therapeutic use)